ACY-241
Drug
Celgene Corporation
Total Payments
$16,068
Transactions
14
Doctors
12
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $8,972 | 2 | 2 |
| 2017 | $7,096 | 12 | 12 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $16,068 | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping mutations (GLORY study) (CC-241-CL-NSCLC-13082) | Celgene Corporation | $8,972 | 2 |
| ACE-MM-200 | Celgene Corporation | $4,170 | 10 |
| ACE-ST-203 | Celgene Corporation | $2,926 | 2 |
Top Doctors Receiving Payments for ACY-241
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Medical Oncology | Fairfax, VA | $5,949 | 2 |
| , MD, PHD | Medical Oncology | Boston, MA | $5,949 | 2 |
| , MD | Hematology & Oncology | Denver, CO | $417.00 | 1 |
| , MD | Hematology & Oncology | San Antonio, TX | $417.00 | 1 |
| , MD | Internal Medicine | Seattle, WA | $417.00 | 1 |
| , M.D., M.P.H.,F.A.C.P | Hematology & Oncology | Atlanta, GA | $417.00 | 1 |
| , MD | Hematology & Oncology | Boston, MA | $417.00 | 1 |
| , MD | Hematology & Oncology | New York, NY | $417.00 | 1 |
| , M.D | Hematology & Oncology | Boston, MA | $417.00 | 1 |
| , M.D | Family Medicine | Salinas, CA | $417.00 | 1 |
| , M.D | Medical Oncology | Tampa, FL | $417.00 | 1 |
| , MD | Internal Medicine | Boston, MA | $417.00 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $16,068
Product Information
- Type Drug
- Total Payments $16,068
- Total Doctors 12
- Transactions 14
About ACY-241
ACY-241 is a drug associated with $16,068 in payments to 12 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $8,972 was paid across 2 transactions to 2 doctors.
The most common payment nature for ACY-241 is "Unspecified" ($16,068, 100.0% of total).
ACY-241 is associated with 3 research studies, including "Phase II study of SCC244 in NSCLC patients harboring MET exon 14 skipping mutations (GLORY study) (CC-241-CL-NSCLC-13082)" ($8,972).